Anti-angiogenic agents in second-line treatment for metastatic colorectal cancer: the optimization of pharmacological costs-Reference-Cited by-同舟云学术

Anti-angiogenic agents in second-line treatment for metastatic colorectal cancer: the optimization of pharmacological costs

Published:2018-05-26 Issue:10 Volume:33 Page:1487-1491
ISSN:0179-1958
Container-title:International Journal of Colorectal Disease
language:en
Short-container-title:Int J Colorectal Dis

Author:

Giuliani Jacopo,Bonetti Andrea

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

http://link.springer.com/article/10.1007/s00384-018-3077-8/fulltext.html

Reference12 articles.

1. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E (2013) European cancer mortality predictions for the year 2013. Ann Oncol 24:792–800

2. Bonetti A, Giuliani J, Muggia F (2014) Targeted agents and oxaliplatin-containing regimens for the treatment of colon cancer. Anticancer Res 34:423–434

3. Schrag D (2004) The price tag on progress-chemotherapy for colorectal cancer. N Engl J Med 351:317–319

4. Kriza C, Emmert M, Wahlster P, Niederländer C, Kolominsky-Rabas P (2013) Cost of illness in colorectal cancer: an international review. PharmacoEconomics 31:577–588

5. Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EG, Piccart MJ (2015) A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 26:1547–1573

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer;Expert Opinion on Drug Safety;2022-01-05

2. Up-to-date role of aflibercept in the treatment of colorectal cancer;Expert Opinion on Biological Therapy;2021-06-13

3. Nitric oxide synthase inhibitors 1400W and L-NIO inhibit angiogenesis pathway of colorectal cancer;Nitric Oxide;2019-02